State-of-the-art update and review: Clinical trials of lipid-lowering agents

American Journal of Cardiology

Volumn 82, Issue 12 A, 1998, Pages 3U-17U

  Kwiterovich, Peter O ^a,b,c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ANTILIPEMIC AGENT; CHOLESTEROL; CLOFIBRATE; COLESTIPOL; COLESTYRAMINE; ESTROGEN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN;

ARTERIOGRAPHY; ATHEROSCLEROTIC PLAQUE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DRUG EFFECT; DRUG SCREENING; DYSLIPIDEMIA; ENDOTHELIUM CELL; HEART INFARCTION; HUMAN; META ANALYSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL;

EID: 0345435041     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)00957-6     Document Type: Conference Paper

References (82)

1. Heart and Stroke Facts: 1996 Statistical Supplement. American Heart Association; 1995.
2. Expert Panel. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993;269:3015-3023.
3. Stamler M, Wentworth D, Neaton JD, for the MRFIT. Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986;256:2823-2828.
4. Levine GN, Keaney JF Jr, Vita JA. Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. N Engl J Med 1995;332:512-521.
5. Holme I, Hjermann I, Helgeland A, Leven P. The Oslo Study: diet and antismoking advice: additional results from a 5-year primary preventative trial in middle-aged men. Prev Med 1985;14:279-292.
6. Committee of Principal Investigators. A cooperative trial in the primary prevention of ischaemic heart disease using clofibrate. Br Heart J 1978;40:1069-1118.
7. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V, et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987;317:1237-1245.
8. Dorr AE, Gunderson KK, Schneider JC Jr, Spencer TW, Martin WB. Colestipol hydrochloride in hypercholesterolemic patients - effect on serum cholesterol and mortality. J Chron Dis 1978;31:5-14.
9. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results: I. Reduction in incidence of coronary heart disease. JAMA 1984;251:351-364.
10. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360-381.
11. Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, Friedewald W. Fifteen-year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245-1255.
12. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988;223:405-418.
13. Buchwald H, Varco RL, Matts JP, Long JM, Fitch LL, Campbell GS, Pearce MB, Yellin AE, Edmiston WA, Smink RD Jr. Effect of partial ileal bypass on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia: report of the Program on Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med 1990;323:946-955.
14. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial Results II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984;251:365-374.
15. Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease: II. Unstable angina, heart failure, primary prevention with aspirin, and risk factor modification. JAMA 1988;260:2259-2263.
16. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 1994;308:367-372.
17. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-1307.
18. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
19. Kjekshus J, Pedersen TR, for the Scandinavian Simvastatin Survival Study Group. Reducing the risk of coronary events: evidence from the Scandinavian Simvastatin Survival Study. Am J Cardiol 1995;76(suppl):64C-68C.
20. Kjekshus J, Pedersen TR, Pyoraia K, for the 4S Group. Impact of hypertension, diabetes and smoking on the effect of simvastatin on coronary events in coronary heart disease patients. Circulation 1995;92(suppl 1):86-94.
21. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olson AG, Thorgeirsson G, The Scandinavian Simvastatin Survival Study (4S) Group. Cholesterol lowering with Simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997;20:614-620.
22. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E, for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol level. N Engl J Med 1996;335:1001-1009.
23. Crouse JR III, Byington RP, Hoen HM, Furberg D. Reductase inhibitor monotherapy and stroke prevention. Arch Intern Med 1997;157:1305-1310.
24. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM, for the AFCAPS/TexCAPS Research Group. JAMA 1998;279:1615-1622.
25. National Center for Health Statistics, Third National Health and Nutrition Examination Survey, 1988-94. US NHANES III Examination Data File [CD-ROM]. Hyattsville, MD: Centers for Disease Control and Prevention; 1996. DHHS public use data file 76200.
26. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998;339:1349-1357.
27. Brensike JF, Levy RI, Kelsey SF, Passamani ER, Richardson JM, Loh IK, Stone NJ, Aldrich RF, Battaglini JW, Moriarty DJ. Effects of therapy with cholestyramine on progression of coronary atherosclerosis: results of the NHLBI Type II coronary intervention study. Circulation 1984;69:313-324.
28. Watts GF, Lewis B, Brunt JN, Lewis ES, Coltart DJ, Smith LD, Mann JI, Swan AV. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St. Thomas' Atherosclerosis Regression Study (STARS). Lancet 1992;339:563-569.
29. Blankenhorn DH, Azen SP, Kramsch DM, Mack WJ, Cashin-Hemphill L, Hodis HN, DeBoer LW, Mahrer PR, Masteller MJ, Vailas LI, et al. Coronary angiographic changes with lovastatin therapy: the Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med 1993;119:967-976.
30. Waters D, Higginson L, Gladstone P, Kimball B, Le May M, Boccuzzi SJ, Lesperance J. Effect of monotherapy with HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis is assessed by serial quantitative arteriography: the Canadian Coronary Atherosclerosis Intervention Trial. Circulation 1994;89:959-968.
31. Pitt B, Mancini GB, Ellis SB, Rosman HS, Park JS, McGovern ME. Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I Investigation. J Am Coll Cardiol 1995;26:1133-1139.
32. The MAAS Investigators. Effect of simvastatin on coronary atheroma: the Multicenter Anti-Atheroma Study (MAAS). Lancet 1994;344:633-638.
33. Barth JD, Zanjee MMB. The REGRESS Research Group. Regression Growth Evaluation Statin Study (REGRESS). Study design and baseline characteristics in 600 patients. Can J Cardiol 1992;8:925-931.
34. Ericsson CG, Hamsten A, Nilsson J, Grip L, Svane B, deFaire U. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996;347:849-853.
35. Herd JA, Ballantyne CM, Farmer JA, Ferguson JJ III, Jones PH, West MS, Gould KL, Gotto AM Jr. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations. Lipoprotein and Coronary Atherosclerosis Study (LCAS). Am J Cardiol 1997;80:278-286.
36. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of colestipol niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987;257:3233-3240.
37. Ornish D, Brown SE, Scherwitz LW, Billings JH, Armstrong WT, Ports TA, McLanahan SM, Kirkeeide RL, Brand RJ, Gould KL. Can lifestyle changes reverse coronary heart disease? Lancet 1990;336:129-133.
38. Brown BG, Albers JJ, Fisher LD, Schaffer SM, Lin J-T, Kaplan C, Zhao X-Q, Bisson BD, Fitzpatrick VF, Dodge HT. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289-1298.
39. Cashin-Hemphill L, Mack WJ, Pogoda MJ, Sanmarco ME, Azen SP, Blankenhorn DH. Beneficial effects of colestipol-niacin on coronary atherosclerosis. JAMA 1990;264:3013-3017.
40. Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RJ. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1990;264:3007-3012.
41. Miller BD, Alderman EL, Haskell WL, Fain JM, Krauss RM. Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford Coronary Risk Intervention Project. Circulation 1996;94:2146-2153.
42. Schuler G, Hambrecht R, Schlierf G, Niebauer J, Hauer K, Neumann J, Hoberg E, Drinkmann A, Bacher F, Grunze M, et al. Regular physical exercise and low-fat diet: effects on progression of coronary artery disease. Circulation 1992;86:1-11.
43. Sacks F, Pasternak RC, Gibson CM, Rosner B, Stone PH. Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolemic patients. Lancet 1994;344:1182-1185.
44. Brown BG, Fuster V. Impact of management in stabilization of coronary disease. In: Fuster V, Ross R, Topol EJ, eds. Atherosclerosis and Coronary Artery Disease. Philadelphia: Lippincott-Raven Publishers, 1996:191-205.
45. Rossouw JE. Lipid-lowering interventions in angiographic trials. Am J Cardiol 1995;76(suppl):86C-92C.
46. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992;326:242-250, 310-318.
47. Brown BG, Zhao X-Q, Sacco DE, Albers JJ. Lipid lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993;87:1781-1791.
48. Liao JK. Endothelium and acute coronary syndromes. Clin Chem 1998;44: 1799-1808.
49. Cannon III, Richard O. Role of nitric oxide in cardiovascular disease: focus on the endothelium. Clin Chem 1998;44:1809-1819.
50. Libby P. Molecular bases of acute coronary syndromes. Circulation 1995; 91:2844-2850.
51. Berliner JA, Navab M, Fogelman AM, Frank JS, Demer LL, Edwards PA, Watson AD, Lusis AJ. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation 1995;91:2488-2496.
52. Anderson TJ, Meredith IT, Yaung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995;332:488-493.
53. Treasure CB, Klein JL, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS, Zhang J, Boccuzzi SJ, Cedarholm JC, Alexander RW. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary heart disease. N Engl J Med 1995;332:481-487.
54. Egashira K, Hirooka Y, Kal H, Sugimachi M, Suzuki S, Inou T, Takeshita A. Reduction in serum cholesterol with pravastatin improves endothelium-dependent vasomotion in patients with hypercholesterolemia. Circulation 1994;89: 2519-2524.
55. Leung W-H, Lau C-P, Wong C-K. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolemic patients. Lancet 1993;341:1496-1500.
56. Vogel RA, Corretti MC, Plotnick GB. Changes in flow-mediated brachial artery reactivity with lowering of desirable cholesterol levels in healthy middle-aged men. Am J Cardiol 1966;77:37-40.
57. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, Sanchez-Pascuala R, Hernandez G, Diaz C, Lamas S. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998;101:2711-2718.
58. Stephens NG, Parsons A, Schofield P, Kelly F, Chesseman K, Mitchinson JM, Brown MJ. Randomized controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996; 347:781-786.
59. Tardif J-C, Cote G, Lesperance J, Bourassa M, Lambert J, Doucet S, for the Multivitamins and Probucol Study Group. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. N Engl J Med 1997;337:365-372.
60. Bhunia AK, Han H, Snowden A, Chatterjee S. Redox-regulated signaling by lactosylceramide in the proliferation of human aortic smooth muscle cells. J Biol Chem 1997;272:15642-15649.
61. Burke AP, Fars A, Malcom GT, Liang Y-H, Smialek J, Virmani R. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med 1997;336:1276-1282.
62. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous vein coronary artery bypass grafts. N Engl J Med 1997;336:153-162.
63. Pedersen TR, Olsson AG, Faergeman O, Kjekshus J, Wedel H, Berg K, Wilhelmsen L, Haghfelt T, Thorgeirsson G, Pyorala K, Miettinen T, Christophersen B, Tobert JA, Musliner TA, Cook TJ. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 1998;97:1453-1460.
64. Anonymous. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998;97:1440-1445.
65. Kwiterovich PO Jr. The antiatherogenic role of high-density lipoprotein cholesterol. Am J Cardiol 1998;82:13Q-21Q.
66. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein-cholesterol levels: the Framingham Study. JAMA 1986;256:2835-2838.
67. Castelli WP, Anderson K, Wilson PW, Levy D. Lipids and risk of coronary heart disease: the Framingham Study. Ann Epidemiol 1992;2:23-28.
68. Castelli WP. Cholesterol and lipids in the risk of coronary artery disease - the Framingham Heart Study. Can J Cardiol 1988;4(suppl):5A-10A.
69. Kannel WB. Metabolic risk factors for coronary heart disease in women: perspective from the Framingham Study. Am Heart J 1987;114:413-419.
70. Pearson TA, Bulkley BH, Achuff SC, Kwiterovich PO, Gordis L. The association of low levels of HDL cholesterol and arteriographically defined coronary artery disease. Am J Epidemiol 1979;109:285-295.
71. Shah PK, Amin J. Low high-density lipoprotein level is associated with increased restenosis rate after coronary angioplasty. Circulation 1992;85:1279-1285.
72. Miller M, Seidler A, Kwiterovich PO, Pearson TA. Long-term predictors of subsequent cardiovascular events with coronary artery disease and "desirable" levels of plasma total cholesterol. Circulation 1992;86:1165-1170.
73. Hayek T, Oiknine J, Dankner G, Brook JG, Aviram M. HDL apolipoprotein A-1 attenuates oxidative modification of low-density lipoprotein: studies in transgenic mice. Eur J Clin Chem Clin Biochem 1995;33:721-725.
74. Bezafibrate Interventional Trial (BIP) presentation at the annual Congress of the European Society of Cardiology. Vienna, Austria, August 21-29, 1998.
75. HDL Intervention Trial (HIT) presentation at the 71st Scientific Sessions of the American Heart Association. Dallas, Texas, November 8, 1998.
76. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglyceride to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Am J Cardiol 1992;70:733-737.
77. Castelli WP. Epidemiology of triglycerides: a view from Framingham. Am J Cardiol 1992;70(suppl):3H-9H.
78. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Res 1996; 3:213-219.
79. Bainton D, Miller NE, Bolton CH, Yarnell JW, Sweetnam PM, Baker IA, Lewis B, Elwood PC. Plasma triglyceride and high-density lipoprotein cholesterol as predictors of ischaemic heart disease in British men: the Caerphilly and Speedwell Collaborative Heart Disease Studies. Br Heart J 1992;68:60-66.
80. Eriksson P, Nilsson L, Karpe F, Hamsten A. Very-low-density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia. Arterioscler Thromb Vasc Biol 1998;18:20-26.
81. Hodis HN, Mack WJ, Azen SP, Alaupovic P, Pogoda JM, LaBree L, Hemphill LC, Kramsch DM, Blankenhorn DH. Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation 1994;90:42-49.
82. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Manttari M, Heinonen OP, Frick MH. Joint effects of serum triglycerides and LDL cholesterol and HDL cholesterol concentration on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation 1992;85:37-46.